Here, we found that conditional knockdown of hepatic PCSK9 suppressed the levels of phosphorylated PI3K, AKT, NF-κB, and AP-1 proteins following hyperlipidemia challenge; this result suggests that PCSK9 knockdown may reduce inflammation by inhibiting the PI3K/AKT signaling pathway. Here, PCSK9 is linked to hyperlipidemia.